What is Pimecrolimus 1% Cream Pacroma® | Elidel Generic
Pacroma® Cream is used to treat eczema (atopic dermatitis) and contains Pimecrolimus 1%. It works by suppressing the activity of certain immune cells that cause inflammation (redness and swelling) of the skin. This relieves itching and improves rashes in atopic dermatitis. Pacroma Cream is used for external use. It should be used 2-4 times a day on the affected area or use it as suggested by the doctor. It should be applied slowly and evenly to the skin until it is rubbed in. You should not use it too often and you should not cover the treated area with a bandage or plaster. You must inform your doctor if there’s no improvement even after two weeks of treatment or if the skin gets worse. It is a safe medicine with few side effects, but you may get an application site reaction like burning, irritation, itching and redness. This medicine is not normally recommended during pregnancy or while breastfeeding unless it is clearly needed.
The FDA recommends the following: This drug should be used only if other drugs have failed or if other medications are not considered appropriate by your doctor. Pimecrolimus 1% should be used on the skin for short treatment periods only. If needed, treatment may be repeated with breaks in between. Use the smallest amount that will treat your condition properly, and apply only on the affected skin. Also, this medication should not be used in children younger than 2 years. As with all medications, discuss the risks, benefits, and proper use of this medication with your doctor.
Brand Names: Elidel
Why use Pimecrolimus 1% Cream Pacroma® | Generic Elidel
Pimecrolimus Elidel generic cream is used to treat certain skin conditions such as eczema (atopic dermatitis) in people who should not use or have not responded to other eczema medications (e.g., topical steroids). Eczema is an allergic-type condition that causes red, irritated, and itchy skin. This drug works by changing the skin’s defense (immune) system, thereby decreasing the allergic reaction that causes eczema. Pimecrolimus belongs to a class of drugs known as topical calcineurin inhibitors (TCIs). This medication is not recommended if you have a history of a certain rare genetic disorder (Netherton’s syndrome). Also, this medication should not be used by anyone who has a weakened immune system (e.g., following an organ transplant).
Pacroma® Cream pimecrolimus cream over the counter may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Pacroma® 1% Pimecrolimus Side Effects
Mild burning or irritation at the application site may occur during the first few days of treatment. Headache may also occur. If any of these effects persist or worsen, notify your doctor promptly. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor immediately if the following unlikely but serious side effects occur: signs of infection (e.g., fever, persistent sore throat). A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any of the following symptoms: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
Ajanta Pharma Limited (APL) is a multinational company based in India engaged in development, manufacturing, and marketing of pharmaceutical formulations. It has a presence in India, the United States, and about 30 other countries in Africa, Asia, the Middle East, and CIS. It was established in 1973. Ajanta Pharma has over 1,400 products registered currently in various countries and an equal number of products are under approval. In India, the company is a branded generic company focused on a few high growth specialty therapies in ophthalmology, dermatology, cardiology, and pain management. Ajanta Pharma exports products to over 30 countries in Asia and Africa. In these markets, the company serves a wide range of therapeutic products in the areas of antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology, and pain management. Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing, and marketing of quality finished dosages. Committed to 'Serve Health Care Needs Worldwide', we produce a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customized to each market we are present in. We clearly understand our customer’s needs and use cutting edge technology to present innovative solutions. Our business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. Ajanta operates 7 state-of-the-art manufacturing facilities in India and Mauritius. 2 of the facilities in India have been successfully approved by the US FDA. We are further expanding our manufacturing capabilities to meet our growth requirement in the future. We employ over 7,500+ people worldwide and our products are sold in over 30 countries. Ajanta’s team members are driven to fulfill its mission; a commitment to ‘Serving Global Healthcare needs with Empathy, Innovation & Technology’.
is Asia's premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world. We have evolved from manufacturing pharmaceuticals like statins and immunosuppressants to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology, and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics. Biocon was among the early movers in the industry to pursue a high-risk strategy of developing biosimilars for global markets. Through our ‘Made in India’ biosimilars business, we seek to pursue a humanitarian path that will provide affordable access to high-quality generic biologics to make a difference to diabetes, cancer and autoimmune diseases. We have succeeded in bringing the benefit of high-quality biosimilars to patients in India, other emerging market countries in Latin America, Africa, the Middle East, and Turkey, Asia-Pacific regions and also now in developed markets of US, EU, and Japan. A combination of specialized talent, state-of-the-art research, and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global biopharmaceutical player. Global Scale
Biocon has created large-scale fermentation capabilities to support the manufacturing of APIs like statins and immunosuppressants. We also built one of India’s largest bio-manufacturing facilities for insulins, monoclonal antibodies, and devices. We continue to invest in expanding our manufacturing capacities to address the growing market need. Biocon’s insulin manufacturing and R&D facility set up in Malaysia with an investment of USD 300 million is the largest integrated insulins facility in Asia. This is the largest foreign investment in biotechnology in Malaysia and respects our commitment to serving patients in different parts of the world.